Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ARDX

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

Is This Under-$10 Stock the Next Big Biotech Winner?

Is This Under-$10 Stock the Next Big Biotech Winner?

This could be the next multibagger hiding in biotech under $10.

This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart

This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart

Ardelyx could be one of the most overlooked small-cap stories of the decade.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential

The risk is high in small-cap growth stocks, but the reward can be transformative.

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

Healthcare Innovation: 3 Biotech Stocks to Watch in May 2023

As the biotech sector is expanding rapidly in response to the growing need for healthcare solutions, fundamentally strong biotech stocks Amicus Therapeutics (FOLD), Ardelyx (ARDX), and Genfit S.A. (GNFT) have the potential to generate substantial returns for investors. Hence, these stocks could be solid watchlist additions this month. Read more….

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ:ARDX) second level of appeal of the Complete Response Letter (CRL) for Xphozah. Ardelyx is seeking approval for Xphozah to control serum phosphorus in adult patients with chronic kidney disease (CKD) on…

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Ardelyx Inc (NASDAQ: ARDX) has

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Ardelyx Inc (NASDAQ:ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial…

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Recursion Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

405,550 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play